Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 27

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 27
---
 Revel has served since January of 2020 as Kadimastem’s Medical Affairs Director. From January 2024, Professor Revel served as a Medical Doctor for Maccabi Health Care Service. Since April 2017, he has served as a Professor of Medicine at Tel Aviv University, a Visiting Professor at Oxford University in the UK from October 2008 to October 2009, and a Visiting Professor at Stanford University in California from October 2015 to October 2016. Additionally, from April 2017 until April 2024, he served at the Assaf Harofeh Medical Center. On April 2017 until April 2021, he served as a Professor at Assaf Harofeh Medical Center. He began his medical career in August 2000 as the head of Fertility Preservation Services at Hadassah Medical Center until May 2017. Professor Revel received his PhD from Tel -AvivUniversity and an MD degree from the Hebrew University of Jerusalem, Israel. Dr. Eric Konofal, MD, Ph.D. (Head of DOXA program):Dr. Eric Konofal has served as NLS’s Chief Scientific Officer since February 2021 and as its Interim Chief Medical Officer since January 2024. Dr. Konofal is an IP expert and co -founderof NLS Pharmaceutics Ltd. Dr. Konofal has been active for more than 30 years in the field of sleep research, including narcolepsy and hypersomnia, as a clinician, scientific researcher, and drug hunter. From 2006 to date, Dr. Konofal has served as a Senior Medical Consultant for the Pediatric Sleep Disorders Center and the Child and Adolescent Psychiatry Department at Robert Debré Hospital (APHP). Dr. Konofal received his MD and PhD from University Pierre -MarieCurie in Paris, France. Proposal:The Board of Directors proposes that the following persons shall be elected, on an advisory basis, as members of the senior management: Mr.Ronen Twito (Executive Chairman and Chief Executive Officer) Prof. Michel Revel, MD, PhD (Chief Scientific Officer) Mr.Kfir Molakandov, PhD (Vice President Research and Development) Mr.Ariel Revel, MD (Director of Medical Affairs) Dr. Eric Konofal, MD, Ph.D. (Head of DOXA program) 12.Compensation for the Members of the Board of Directors and Executive Management 12.1 Approval of the Compensation for the Board